Patrick Bez, Bas Smits, Christoph Geier, Aleksandra Hirsch, Andrés Caballero de Oyteza, Michele Proietti, Bodo Grimbacher, Martin Wolkewitz, Sigune Goldacker, Klaus Warnatz
{"title":"Uncovering risk factors of premature mortality in Common Variable Immunodeficiency (CVID).","authors":"Patrick Bez, Bas Smits, Christoph Geier, Aleksandra Hirsch, Andrés Caballero de Oyteza, Michele Proietti, Bodo Grimbacher, Martin Wolkewitz, Sigune Goldacker, Klaus Warnatz","doi":"10.1016/j.jaip.2025.03.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Among patients with common variable immunodeficiency (CVID) patients with complications of immune dysregulation (CVIDc) have higher mortality rates compared to those with infection-only presentation (CVIDio). Therefore, identifying predictive markers of premature mortality among CVIDc patients is crucial.</p><p><strong>Objective: </strong>The purpose of this retrospective exploratory study was to describe the mortality in a large tertiary referral center and compare the clinical and laboratory characteristics of CVIDc patients who died prematurely with a group of matched living CVIDc control patients to identify potential indicators of premature death.</p><p><strong>Methods: </strong>The study included patients diagnosed with CVID according to ESID criteria and active follow-up. In a case-control analysis, we identified patients who died before the age of 70 years as cases, and then randomly selected controls who were matched for sex, age, and CVID phenotype.</p><p><strong>Results: </strong>We were able to confirm the poor prognosis of CVIDc compared to CVIDio in 497 patients, including 57 who had died. The most common causes of death were infections and neoplasia. The exploratory case-control analysis of 37 cases and 73 controls suggests that cases had a higher prevalence of severe enteropathy, hepatopathy, and neoplasia when compared with controls three years prior to death. This was associated with a higher frequency of lymphopenia, thrombocytopenia, and liver enzyme elevation.</p><p><strong>Conclusion: </strong>Hepatopathy and severe enteropathy need to be confirmed in a multicenter prospective study as the most relevant factors associated with premature mortality in CVIDc patients. Their early evaluation will hopefully allow for better and possibly more definitive treatment options.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaip.2025.03.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Among patients with common variable immunodeficiency (CVID) patients with complications of immune dysregulation (CVIDc) have higher mortality rates compared to those with infection-only presentation (CVIDio). Therefore, identifying predictive markers of premature mortality among CVIDc patients is crucial.
Objective: The purpose of this retrospective exploratory study was to describe the mortality in a large tertiary referral center and compare the clinical and laboratory characteristics of CVIDc patients who died prematurely with a group of matched living CVIDc control patients to identify potential indicators of premature death.
Methods: The study included patients diagnosed with CVID according to ESID criteria and active follow-up. In a case-control analysis, we identified patients who died before the age of 70 years as cases, and then randomly selected controls who were matched for sex, age, and CVID phenotype.
Results: We were able to confirm the poor prognosis of CVIDc compared to CVIDio in 497 patients, including 57 who had died. The most common causes of death were infections and neoplasia. The exploratory case-control analysis of 37 cases and 73 controls suggests that cases had a higher prevalence of severe enteropathy, hepatopathy, and neoplasia when compared with controls three years prior to death. This was associated with a higher frequency of lymphopenia, thrombocytopenia, and liver enzyme elevation.
Conclusion: Hepatopathy and severe enteropathy need to be confirmed in a multicenter prospective study as the most relevant factors associated with premature mortality in CVIDc patients. Their early evaluation will hopefully allow for better and possibly more definitive treatment options.
期刊介绍:
JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases.
This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders.
The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.